Reviva Pharmaceuticals (NASDAQ:RVPH) Given New $4.00 Price Target at HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH) had its target price lowered by HC Wainwright from $11.00 to $4.00 in a report released on Monday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also commented on the company. Benchmark dropped their price target on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. Maxim Group dropped their price target on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 15th. D. Boral Capital dropped their price target on Reviva Pharmaceuticals from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, September 19th. Roth Capital reaffirmed a “buy” rating and issued a $3.00 price target (down previously from $7.00) on shares of Reviva Pharmaceuticals in a research note on Monday, August 18th. Finally, Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $3.86.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.59 on Monday. The firm has a market cap of $41.02 million, a PE ratio of -0.91 and a beta of -0.08. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. The business has a 50 day moving average price of $0.49 and a 200-day moving average price of $0.60.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Research analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RVPH. BluePointe Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 354.7% in the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after purchasing an additional 36,807 shares in the last quarter. Private Advisor Group LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth about $191,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth about $58,000. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. Finally, Persistent Asset Partners Ltd raised its position in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.